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Summary Introduction
A deletion in the tumor-suppressor gene, RB, discovered Retinoblastoma results from homozygous inactivation
by quantitative multiplex PCR, shows low penetrance of both alleles of the RB tumor-supressor gene in devel-
(LP), since only 39% of eyes at risk in this family develop oping human retina. In Ç50% of patients, both alleles
retinoblastoma. The 4-kb deletion spanning exons 24 are mutated in only the single retinal cell that forms the
and 25 (D24–25) is the largest ever observed in an LP tumor. In the other patients, the ﬁrst allele is mutated
retinoblastoma family. Unlike the usual RB mutations, in the germ line, as either a new or an inherited muta-
which cause retinoblastoma in 95% of at-risk eyes and tion. The second allele is mutated in several developing
yield no detectable protein, the D24–25 allele tran- retinal cells as a stochastic event following a Poisson
scribed a message splicing exon 23 to exon 26, resulting distribution (Knudson 1971), leading to multiple tu-
in a detectable protein (pRBD24–25) that lacks 58 amino mors, usually bilateral, in family members with the
acids from the C-terminal domain, proving that this do- germ-line mutation. In 70% of retinoblastoma tumors,
main is essential for suppression of retinoblastoma. Two the second hit is loss of heterozygosity (LOH), with
functions were partially impaired by D24–25—nuclear duplication of the mutant allele by nondisjunction or
localization and repression of E2F—consistent with the mitotic recombination (Cavenee et al. 1983; Zhu et al.
idea that LPmutations generate ‘‘weak alleles’’ by reduc- 1989), but 30% of the time the second hit is a different
ing but not eliminating essential activities. However, mutation. The common type of RB mutations lead to
D24–25 ablated interaction of pRB with MDM2. Since premature STOP codons and presumed truncated pro-
a homozygous LP allele is considered nontumorigenic, teins (pRB), which are not detectable in retinoblastoma
the pRB/MDM2 interaction may be semi- or nonessen- tumors (Dunn et al. 1989; Horowitz et al. 1990). Such
tial for suppressing retinoblastoma. Alternatively, some mutations manifestú95% penetrance in families (Gallie
homozygous LP alleles may not cause tumorigenesis be- et al. 1995).
cause an additional event is required (the ‘‘three-hit hy- In uncommon, low-penetrance (LP) families, a sig-
pothesis’’), or the resulting imbalance in pRB function niﬁcant proportion of obligate carriers develop either
may cause apoptosis (the ‘‘death allele hypothesis’’). no tumors or only unilateral tumors (Macklin 1960;
pRBD24–25 was also completely defective in suppress- Strong et al. 1981; Connolly et al. 1983; Onadim et al.
ing growth of Saos-2 osteosarcoma cells. Targeting 1990, 1991, 1992; Sakai et al. 1991; Munier et al. 1992;
pRBD24–25 to the nucleus did not improve Saos-2 growth Lohmann et al. 1994). In some families, tumors in dis-
suppression, suggesting that C-terminal domain func- tantly related individuals are caused by distinct, sporadic
tions other than nuclear localization are essential for RB mutations: these are examples of pseudo-LP pedi-
blocking proliferation in these cells. Since D24–25 be- grees (Dryja et al. 1993; Munier et al. 1993; Bia and
haves like a null allele in these cells but like an LP allele Cowell 1995). Genuine LP has been attributed to a de-
in the retina, pRB may use different mechanisms to con- layed second hit (Knudson 1971; Herrman 1976), host
trol growth in different cell types. resistance factors (Matsunaga 1978), immunological ef-
fects (Gallie et al. 1979), and ‘‘weak alleles’’ (Sakai et
al. 1991; Gallie et al. 1995).
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Therefore, individuals with a germ-line LP RB mutation and RNA from either these cells or peripheral blood
lymphocytes were as described elsewhere (Goddard etwould have a reduced chance of developing retinoblas-
toma tumors, since LOH would be insufﬁcient for tu- al. 1988; Dunn et al. 1989).
morigenesis. Fragment Analysis
The RB mutations have been identiﬁed in several LP
Fragment analysis involves ampliﬁcation of the pro-retinoblastoma families and support the weak-allele hy-
moter region and all 27 exons of RB with ﬂuorescein-pothesis, since each is in-frame and would result in de-
labeled primers in multiplex sets. Multiplex PCR wastectable pRB. Three families have point mutations in the
performed by use of an approach similar to that de-promoter region, which markedly reduce but do not
scribed elsewhere (Group 1992; Ioannou et al. 1992;extinguish promoter activity (Sakai et al. 1991; Cowell
Schwartz et al. 1992). A 50-ml reaction mixture con-et al. 1996). Several mutations within the RB coding
tained 0.5 mg of genomic DNA, 150 ng of each primer,region are associated with LP: Arg661Trp (exon 20) in
3.6 mM each dNTP, 10% dimethyl sulfoxide, 16 mMthree separate families (Lohmann et al. 1992; Onadim et
(NH4)2SO4, 67 mM Tris-HCl (pH 8.8), 6.7 mM MgCl2,al. 1992), Cys712Arg (exon 21) (authors’ unpublished
42.5 mg of BSA, 1 mM b-mercaptoethanol, 6.8 mMdata), and deletion of Asn480 (exon 16). These muta-
EDTA (pH 8.0), and 5 units of Taq DNA polymerase.tions lie within the important pocket domain (exons 12–
One primer of each pair was ﬂuorescein-labeled at the22) (Hu et al. 1990), which characterizes the RB gene
5 end. Samples were denatured at 94C for 3 min andfamily (Ewen et al. 1991; Hannon et al. 1993; Li et al.
were ampliﬁed by 18 PCR cycles (94C for 50 s, 52C1993; Mayol et al. 1993). The pocket domain is critical
for 50 s, and 72C for 2 min) and a ﬁnal elongationfor transcriptional repression (Hamel et al. 1992; Hie-
cycle of 70C for 10 min. Seven microliters of each PCRbert et al. 1992; Flemington et al. 1993; Helin et al.
product was added to 7 ml of loading buffer, denatured1993; Adnane et al. 1995; Bremner et al. 1995), growth
for 2 min at 100C, rapidly cooled on ice, and electro-suppression by pRB (Templeton et al. 1991; Qian et al.
phoresed on a 6% polyacrylamide gel run on a Phar-1992; Qin et al. 1992), and interaction of pRB with a
macia A.L.F. sequencer to detect subexonic deletionsvariety of viral and cellular proteins (DeCaprio et al.
and insertions. To detect whole-exon deletion or dupli-1988; Whyte et al. 1988; Dyson et al. 1989; Hu et al.
cation, each multiplex set of three to seven pairs of RB1990; Defeo-Jones et al. 1991; Huang et al. 1991; Qian
exon primers also contained control primers for C4,et al. 1992; Qin et al. 1992; Dowdy et al. 1993; Ewen
which amplify exon 4 of the retinaldehyde-binding pro-et al. 1993; Hagemeier et al. 1993a; Wang et al. 1993).
tein gene on chromosome 15. Four external controlsAn exon 4 deletion causing LP retinoblastoma results in
were also tested, by use of DNA known to be nullisomicloss of 40 amino acids from the N-terminal portion (N-
(WERI-RB1 cells) (McFall et al. 1977), monosomic (EL)domain) of pRB (Dryja et al. 1993); in vitro–generated
(Benedict et al. 1983), diploid (normal), and trisomicmutations overlapping this region render pRB defective
(ALI) (authors’ unpublished data) for RB. The numberin growth suppression and phosphorylation (Hamel et
of copies of a fragment in a test sample was calculatedal. 1990; Qian et al. 1992).
by comparing ﬂuorescence intensity of the fragmentUsing analysis of size and copy number of each exon
with these standards. Fragment detection and subse-and the promoter, we have identiﬁed a large RB deletion
quent calculations were performed automatically byspanning exons 24 and 25 (D24–25) as the causative
Fragment Manager 2.1 (Pharmacia).mutation in a large LP family. We deﬁne several func-
tions and interactions for which pRBD24–25 is deﬁcient Long PCR
because of the protein domains that are missing. Nuclear Long PCR (Barnes 1994; Cheng et al. 1994) was per-
localization and repression of E2F-mediated transcrip- formed by use of a Perkin-Elmer kit with intron 23
tion are partially impaired, indicating that thisRB muta- primer GGG AAG TAG TAA AGA ATG AGA GGG
tion is indeed ‘‘weak.’’ Interaction with the MDM2 pro- GGA TTA and intron 26 primer ATG CAT AAA CAA
tein was ablated, an observation that has led us to ACC TGC CAA CTG AAG AAA. Target fragments
suggest new models for LP retinoblastoma. Although were ampliﬁed from 500 ng of genomic DNA in a 100-
D24–25 is associated with an LP phenotype in the ret- ml reaction. Other components were as speciﬁed by the
ina, this allele behaves like a null allele in the assay for kit manufacturer. Two-step PCR was performed (20 cy-
growth suppression of an osteosarcoma cell line, Saos-2. cles of 94C for 1 min and 64C for 10 min, followed
Thus, pRB may not use the same mechanism to suppress by 17 cycles of 93C for 1 min and 62C for 10 min,
growth in different cell types. with a ﬁnal extension at 72C for 9 min).
Material and Methods Reverse Transcriptase–PCR, Subcloning, and
SequencingCell Culture and Nucleic-Acid Preparation
Ten micrograms of RNA from normal and carrierBoth culture of Epstein-Barr virus (EBV)–trans-
formed lymphocytes and preparation of genomic DNA EBV-transformed lymphocytes was reverse-transcribed
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by use of 1.5 mg of oligo(dT) as primer and 60 units of 18 bp of which hybridizes to codons 776–781 at the
start of exon 23, and primer GEX3 (5-GAG CTG CATavian myeloblastosis virus reverse transcriptase for 90
min at 42C. One-tenth of the resulting cDNA was am- GTG TCA GAG GT), which hybridizes to a region 3
of the pGEX-2Tmultiple cloning site. The resulting PCRpliﬁed in the presence of primers JD2 (GGA ATT CAC
CCC TGA AGA GTC C) and ORB5 (CGG GGA TCC fragment was cut with EcoRI and ligated into EcoRI-
digested pGEX-2T to generate pGSTRB23–27. TheAGA GGT GTA CAC AG), which hybridize to se-
quences in exons 23 and 27, respectively. The sense same 5 primer was used to construct pGSTRB23–
27D24–25, but the template was SVhRBHAD24–25, andprimer (JD2) contains an EcoRI site whereas the anti-
sense primer (ORB5) contains a BamHI site. Ampliﬁca- the 3 primer (ORB6) hybridized at the 3 end of the
RB cDNA (5-G CCG GAA TTC TCA TTT CTC TTCtion of wild-type and D24–25 RNA with these primers
generates 420-bp and 246-bp fragments, respectively. CTT GTT). The PCR fragment was digested with EcoRI
and cloned into EcoRI-digested pGEX-2T. Inserts wereThese fragments were gel-puriﬁed, digested with
EcoRI/BamHI, subcloned into pGEM7 (Promega), and checked by sequencing.
sequenced with T7 and SP6 primers.
Nuclear Localization
Western Analysis Immunostaining using horseradish peroxidase (HRP)–
conjugated secondary antibody followed by DAB/H2O2Detection of pRB from EBV-transformed lysates was
performed as described elsewhere (Bremner et al. 1995). reaction was as described elsewhere (Zacksenhaus et al.
1993). The monoclonal anti-pRB (14001A) recognizesFifty micrograms of total protein was loaded per lane.
an epitope in the N-terminus of pRB (amino acids 300–
Vectors Expressing pRB 380; PharMingen). HRP-conjugated goat anti-mouse
secondary antibody was from Bio-Rad. The expressionIn order to further analyze the function of D24–25, we
made plasmid vectors, SVhRBHA and SVhRBHAD24–25, vectors (10 mg) were transfected in duplicate into Saos-
2 cells and were stained for localization of pRB.expressing pRB from the SV40 promoter. SVhRBHA
was built in two steps. First, the C-terminal coding por-
Repression of E2 Promoter Elementstion of the RB cDNA was ampliﬁed by use of primers
(ORB1, 5-GGC CAA GCT TCT CCG GCT AAA TAC The pE2(080/070)CAT reporter plasmid, which con-
sists of two E2F sites upstream of a TATA box and theACT T; and ORB2, 5-CCC GAA TTC CCA TTT CTC
TTC CTT GTT T), which introduced a HindIII site and chloramphenicol actyltransferase (CAT) gene (Bremner
et al. 1995), was transfected into RB0/0 C33A cells (cer-an EcoRI site at the 5 and 3 end of the fragment,
respectively. The 3 primer also changed the stop codon vical carcinoma), together with varying amounts of the
D21, SVhRBHA, or SVhRBD24–25HA plasmids. The re-to TGG. The HindIII/EcoRI fragment was subcloned
into HindIII/EcoRI-digested pECE-HA (a gift from P. sultant promoter activity was assessed by measurement
of CAT levels, as described elsewhere (Bremner et al.Hamel), thereby adding a hemagluttinin (HA) tag onto
the 3 end of the RB sequence. The insert was checked 1995).
for PCR errors by sequencing. The RB fragment, to-
MDM2 Bindinggether with the SV40 poly-A tail present in pECE-HA,
was excised by DraIII/BamHI digestion and was sub- GST fusion proteins were prepared as described else-
where (Zacksenhaus et al. 1993). 35S-labeled in vitrocloned into DraIII/BamHI-digested SVhRB (Bremner et
al. 1995). The same strategy was used to generate translated (IVT) human MDM2 was generated by use of
the TNT reticulocyte system (Promega) and the plasmidSVhRBHAD24–25, except that D24–25 cDNA was used
as a template for the initial PCR. To build the /nuclear pHDM1A (a gift from A. Levine). Twenty microliters
of IVT MDM2 was incubated with 1 mg of GST or GSTlocalization–signal (NLS) versions of these plasmids, the
parent plasmid was partially digested with EcoRI, and fusion protein in 0.5 ml of binding buffer (0.5% NP-
40, 20 mM Tris pH 8.0, 100 mM NaCl, and 0.5 mMan oligomer, encoding the SV40 large T NLS, was in-
serted between the RB cDNA and the HA tag: sense EDTA) at 4C for 1 h. Twenty microliters of glutathi-
one-Sepharose–bead slurry (Pharmacia), prewashed instrand, 5-AA TTC ATC GAT AAG AAA AAG CGG
AAG GTC G; and antisense strand, AA TTC GAC CTT binding buffer, was added, and the suspension was
rocked at 4C for 30 min. Bead-protein complexes wereCCG CTT TTT CTT ATC GAT G. Constructs were
conﬁrmed by sequencing. spun at 2,000 g in a microfuge, washed four times with
binding buffer, boiled in a 30-ml sample buffer, and ana-Glutathione-S-transferase (GST) expression vectors
were constructed by use of pGEX-2T (Pharmacia). A lyzed by SDS-PAGE. The presence of equal amounts
of different GST proteins was conﬁrmed by CoomassieGST-RB plasmid containing exons 19–27 of human RB
cDNA (R. Bremner, unpublished data) was used as a staining. IVT MDM2 was detected by autoradiography
and was quantiﬁed by use of a Molecular Dynamicstemplate for ampliﬁcation with primer RB776 (5-GGC
GGA ATT CCC CCT ACC TTG TCA CCA), the last phosphorimager.
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Figure 1 RBF65 pedigree. Only blood relatives are shown. In selected cases, numbers assigned to different individuals are shown above
the symbol. Some symbols represent two or more family members; this is indicated by a number within the relevant symbol. Genotypes that
were determined by fragment analysis are indicated below the symbols.
Saos-2 Growth-Suppression Assay one child (II-8) developed unilateral RB, 17 of his
descendants are known, by clinical analysis or by theFour 60-mm dishes of Saos-2 cells were transfected
molecular testing described below, to carry a mutantwith 10 mg of the RB expression vector, together with
RB allele. Only 11 of the 18 developed retinoblas-1 mg of pBABEpuro, which confers puromycin resis-
toma (61% penetrance), only 3 had bilateral tumorstance, and 0.5 mg of cytomegalovirus b-galactosidase
(low expressivity), and 1 had retinoma (Gallie et al.(CMVbgal), which expresses b-galactosidase. Trans-
1982a, 1982b). Thus, 14/36 (39%) of at-risk eyesfection efﬁciency was assessed by measurement of
developed retinoblastoma.b-galactosidase activity on one of the four plates 2 d
The diseased-eye ratio (DER) is deﬁned as the meanafter transfection. Cells on the other plates were
number of diseased eyes per carrier (Lohmann et al.treated with puromycin for 18 d, and ﬂat cells were
1994) and represents a combination of penetrance andcounted and normalized to b-galactosidase activity.
expressivity that is particulary useful in retinoblastoma,
in which the two eyes develop independent tumors. Ad-Results
ditional data on the precise number of tumors in an
Penetrance and Expressivity of the RBF65 Pedigree individual is not usually available and, in any case,
The large Canadian family, RBF65, has been de- would be less clearly interpreted than the number of
scribed elsewhere, indicating linkage of retinoblas- eyes affected. Families with the usual, high-penetrance
toma to chromosome 13q14 (Connolly et al. 1983). retinoblastoma have DER valuesú1.0 and, in most ped-
The pedigree now includes ú120 blood relatives over igrees, close to 2.0 (Lohmann et al. 1994). The DER
four affected generations (ﬁg. 1). The ﬁrst-generation for RBF65 is .78, typical of LP retinoblastoma families
(Lohmann et al. 1994).carrier (I-2) was implicated because, although only
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Deletion of Exons 24 and 25 in an Individual from was positive for D24–25. Fragment analysis of DNA
from amniotic ﬂuid revealed that the fetus, IV-35, wasFamily RBF65, Detected by Fragment Analysis
unaffected (ﬁg. 1). Prior to identiﬁcation of D24–25, 25The RBmutation of family RBF65 was found by anal-
children in this family had been undergoing intensiveysis of blood from patient IV-9 (unilateral retinoblas-
clinical screening for tumors; the molecular test showedtoma) (ﬁg. 1), by quantitative multiplex PCR of exon
that only two children were at risk and needed the clini-sets (fragment analysis), which efﬁciently identiﬁes dele-
cal screening for tumors. Each of these children devel-tions, insertions, and changes in copy number of exons
oped one tumor in one eye, each treated successfullyor the promoter. More than 30% of RB mutations are
with only laser. This has resulted in a signiﬁcant decreasedetected by fragment analysis (authors’ unpublished
in health-care costs for this family (Noorani et al. 1996).data). A multiplex set comparing copy number with that
of a control fragment (C4; chromosome 15) detected
A 4-kb Genomic Deletion Encompassing Exons 24two copies of exons 3, 9, 13, 20, and 23 but only one
and 25copy of exon 24 (data not shown). A second multiplex
To characterize the extent of the deletion, we per-set detected two copies of exon 26 but only one copy
formed Long PCR (Barnes 1994; Cheng et al. 1994) onof exon 25 (data not shown). These data suggested that
genomic DNA from affected and unaffected individuals.IV-9 carried a heterozygous deletion of exons 24 and
Ampliﬁcation of normal DNA with primers in introns25 (D24–25).
23 and 26 generated the predicted fragment of 12 kb
Deletion of Exons 24 and 25 in Family RBF65: (ﬁg. 2, lanes 2, 14, 16, 20, and 21). An additional frag-
Segregation with the Disease ment of Ç8 kb was detected in whole blood of D24–
25 carriers (ﬁg. 2, lanes 3–13 and 17–19). This resultMolecular testing by fragment analysis was performed
suggests that D24–25 individuals carry a heterozygouson 35 members of family RBF65. Ten individuals who
4-kb deletion encompassing the 3 end of intron 23, thehad clinical evidence of an RB mutation, as well as the
whole of exon 24, introns 24 and 25, and the 5 end ofthree unaffected second-generation relatives who were
intron 25 (ﬁg. 2).predicted to be carriers because they had affected de-
scendants (ﬁg. 1), all showed heterozygosity for D24–
Expression of the D24–25 Allele25 (RB//D24–25). Signiﬁcantly, among the other 22 family
Deletion of exons 24 and 25 predicts in-frame splicingmembers studied, two previously unsuspected individu-
of exons 23 and 26, leading to a transcript 174 bpals were found to carry D24–25: II-1 has three unaf-
shorter than wild type and to a stable, internally deleted,fected children who do not have D24–25, and IV-40
protein. Most mutated RB transcripts, unlike normalhas no descendants (ﬁg. 1). The remaining 20 at-risk
transcripts, are not detectable in EBV-transformed lym-relatives who were shown not to have D24–25 have a
phocytes (Dunn et al. 1989), presumably because of in-total of 90 descendants, all free of retinoblastoma or
stability of mRNA undergoing premature terminationretinoma. Thus, carriers of D24–25 do not necessarily
of translation (Schneider et al. 1994).develop retinoblastoma, but those with retinoblastoma
EBV-transformed RB//D24–25 lymphocytes from IV-9or retinoma in this family always have D24–25. These
and control normal (RB///) lymphocytes were used toﬁndings are convincing evidence that, in the RBF65 pedi-
prepare total RNA. Samples were reverse-transcribedgree, D24–25 is the allele that causes LP retinoblastoma.
with random hexanucleotides and were ampliﬁed with
Melanoma Tumor: No LOH for D24–25 primers speciﬁc for exons 20 and 27 of RB. Only the
wild-type 420-bp fragment was detected by use of RNANo retinoblastoma tumor is available for study from
obtained from the normal individual (ﬁg. 3A, lane 1).this family, since at-risk individuals are clinically moni-
In contrast, both the wild-type 420-bp fragment and atored for tumors from birth, allowing small tumors to be
246-bp fragment were detected in RNA from the RB//treated without removal of the eyes. The large metastatic
D24–25 cells (ﬁg. 3A, lane 3). The truncated fragment wasmelanoma that arose in individual III-9 was studied by
subcloned; in three of the resultant plasmids, accurateuse of DNA prepared from parafﬁn-embedded, forma-
splicing between exons 23 and 26 was documented bylin-ﬁxed tumor tissue and showed both wild-type and
sequencing (ﬁg. 3B and C).D24–25 alleles, with no evidence of LOH (data not
D24–25 predicts in-frame loss of the 58 codons forshown). It is unlikely that the wild-type allele detected
amino acids 830–887 (ﬁg. 3C). The resultant protein,in this assay was derived from contaminating normal
pRBD24–25, should beÇ6 kD shorter than wild-type pRB.tissue, since histological analysis revealed only tumor
To test this prediction, cell lysates from EBV-trans-cells in the area used to prepare DNA.
formed RB/// and RB//D24–25 lymphocytes were ana-
Prenatal Diagnosis of an Unaffected Fetus lyzed by western blotting using an anti-pRB monoclonal
antibody. Only the wild-type 110-kD unphosphorylatedIdentiﬁcation of the causative mutation allowed us to
offer prenatal diagnosis to III-26, who had retinoma and and slowly migrating hyperphosphorylated forms of
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Figure 2 Identiﬁcation of a 4-kb deletion in D24–25 carriers, by long PCR. DNA from 14 members of the pedigree was analyzed by
long PCR. Pedigree symbols are as shown in ﬁgure 1. Normal controls (N) were run in lanes 2, 14, 16, and 21. A 1-kb ladder was used as a
marker (M). The wild-type (WT) 12-kb and mutant (Mut) 8-kb bands are indicated. A schematic diagram of the ampliﬁed region is shown
below the gel. Primers used in the PCR are represented by arrows; and exons are represented by blackened boxes. The approximate site of the
4-kb deletion is indicated.
pRB (Buchkovich et al. 1989; Chen et al. 1989; DeCa-
prio et al. 1989) were detected in RB/// lysates. How-
ever, in lysates of RB//D24–25 cells, an additional lower
band was detected at Ç104 kD (ﬁg. 3D). Thus, in EBV-
transformed lymphocytes, the D24–25 allele is ex-
pressed at both RNA and protein levels.
‘‘Weak-Allele’’ Characteristics of D24–25
The simplest type of weak allele is one that partially
impairs one or more essential pRB functions. We discov-
ered two pRB properties that are impaired but not ab-
lated by D24–25.
1. Nuclear localization.—Previously, we had mapped
the pRB NLS to a 17-amino-acid motif encoded within
exon 25 (Zacksenhaus et al. 1993). In the absence of the
NLS, pRB is distributed between cytoplasm and nucleus.
When the pocket domain is also mutated, pRB localizes
exclusively to the cytoplasm (Zacksenhaus et al. 1993).
Because immunostaining for pRB in RB//D24–25 lympho-
cytes was inconclusive, we transfected the plasmids
Figure 3 Expression of D24–25 at the RNA and protein levels. SVhRBHA and SVhRBD24–25HA (expressing pRB and
A, RT-PCR analysis of RNA from EBV-transformed normal (lane 1) pRBD24–25, respectively) into Saos-2 cells, followed by
or heterozygous (lane 3) lymphocytes. The 1-kb ladder was used as a immunostaining with the pRB monoclonal antibody.
marker (M). Wild-type 420-bp and D24–25 246-bp fragments are
Wild-type pRB was found exclusively in the nucleus (ﬁg.indicated. B, Sequence of the D24–25 fragment ampliﬁed in panel A.
4A), whereas pRBD24–25 was both nuclear and cyto-The end of exon 23 and the start of exon 26 are shown. C, Diagram
showing consequences of the D24–25 mutation. The reading frame plasmic (ﬁg. 4B), resembling the distribution of pRBDNLS
is not altered; fusion of the last two bases in exon 23 with the ﬁrst that lacked the NLS (Zacksenhaus et al. 1993).
base in exon 26 regenerates codon 888; and codons 830–887 are 2. E2F repression.—The pRB pocket alone binds free
deleted. D, Western analysis of protein from EBV-transformed normal
E2F, but both the pocket and the C-domain are required(lane 1) or heterozygous (lane 2) lymphocytes. Wild-type and mutant
to bind E2F on DNA (Hiebert 1993). Therefore, weproteins are indicated. Another EBV-transformed line, from a separate
individual, gave the same result (data not shown). tested the ability of pRBD24–25 to interact with E2F in a
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Figure 5 Repression of E2F by pRBD24–25: partially reduced rela-
tive to wild-type pRB but not eliminated. C33A cells were transfected
with 2 mg of the reporter plasmid pE2(080/070)CAT together with
either a control vector SVLuc (Bremner et al. 1995) or various amounts
of the indicated RB plasmids, and CAT activity was measured. Fold
repression is relative to the CAT activity obtained with the controlFigure 4 Localization of pRBD24–25, shown to be partially aber-
vector. An equivalent number of moles of SV40 promoter was usedrant. Saos-2 cells were transfected with vectors expressing wild-type
in each transfection, by including, where necessary, SVLuc as a ﬁllerpRB (A) or pRBD24–25 (B). Forty-eight hours later the subcellular loca-
plasmid.tion of these proteins was determined by immunostaining with an
anti-pRB monoclonal antibody.
27D24–25). Resultant complexes were puriﬁed on gluta-
function assay. The E2-CAT reporter plasmid was trans- thione-Sepharose beads, and MDM2 binding was as-
fected into RB0/0 C33A cells, together with varying sessed by PAGE and autoradiography. MDM2 bound
amounts of the plasmids expressing wild-type pRB, GST23–27 (ﬁg. 6, lane 3) but showed negligible interac-
pRBD24–25, or D21 (expressing a mutant version of pRB, tion with GST23–27D24–25, similar to the result obtained
which lacks exon 21 and does not bind E2F). The resul-
tant promoter activity was assessed by measurement of
CAT levels. pRBD24–25 retained some ability to repress
E2F-mediated transcription—unlike D21, which did not
affect E2F-mediated transcription (ﬁg. 5).
MDM2: Failure to Bind to pRBD24–25
Mdm2 is a proto-oncogene that was originally iso-
lated from a spontaneously transformed mouse cell line
(Fakharzadeh et al. 1991). It cooperates with activated
ras to transform primary rat-embryo ﬁbroblasts (Finlay
1993) and is ampliﬁed in 30%–40% of human sarco-
mas (Oliner et al. 1992; Ladanyi et al. 1993; Leach et
al. 1993; Reifenberger et al. 1993; Cordon-Cardo et al.
1994). Expression of an MDM2 transgene in the lactat-
ing mammary inhibits gland development and promotes
polyploidy and tumorigenesis (Lundgren et al. 1997).
The tumorigenic effects of MDM2 may be due, in part,
to its ability to bind and inactivate pRB (Xiao et al.
Figure 6 D24–25 ablation of interaction of pRB with MDM2.1995). Since this interaction is mediated by residues
The schematic diagram indicates the position of the MDM2-binding792–928 of the pRB C-domain (Xiao et al. 1995), we
domain (Xiao et al. 1995), the exon 23–27 portion of pRB (presenttested whether it is disrupted by D24–25.
in GST23–27), and the same region with the D24–25 mutation (pres-
IVT MDM2 was incubated with either GST alone, ent in GST23–27D24–25). IVT MDM2 was incubated with the indi-
GST fused to the C-domain of pRB (GST23–27), or cated GST protein, and bound complexes were puriﬁed and analyzed
by SDS-PAGE and autoradiography.the C-domain lacking amino acids 830–887 (GST23–
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with GST alone (ﬁg. 6, compare lanes 2 and 4). Quanti-
tation by Phosphorimager conﬁrmed that interaction of
GST23–27D24–25 with IVT MDM2 was equivalent to
background levels (data not shown).
Ablation of MDM2 binding by D24–25 is surprising,
given that this mutation is a weak, not null, allele. Possi-
ble explanations, including newmodels of LP retinoblas-
toma, are outlined in the Discussion.
pRBD24–25: Failure to Suppress the Growth
of Saos-2 Cells
Saos-2 cells express a truncated, nonfunctional pRB
(Shew et al. 1990). Overexpression of wild-type RB in
Saos-2 causes growth arrest in G1, manifested by ﬂat-
tening and enlargement of transfected cells (Goodrich
et al. 1991; Templeton et al. 1991; Qian et al. 1992;
Qin et al. 1992). To assay biological activity, Saos-2
cells were transfected with the SVhRBHA or SVhRBD24–
25HA expression vectors and pBABEpuro, which confers
resistance to the drug puromycin, and by CMVbgal, to
control for transfection efﬁciency. Transfected cells were
selected in puromycin and were analyzed microscopi-
cally. Figure 7 D24–25 ablation of suppression of Saos-2 cell growth
As expected (Buchkovich et al. 1989; Chen et al. by pRB. A, Saos-2 growth assay. Four 60-mm dishes of Saos-2 cells
were transfected with 10 mg of the indicated RB plasmids, together1989; DeCaprio et al. 1989; Templeton et al. 1991;
with 1 mg of pBABEpuro, which confers puromycin resistance, andHinds et al. 1992; Qian et al. 1992; Qin et al. 1992;
0.5 mg of CMVbgal, which expresses b-galactosidase. TransfectionZacksenhaus et al. 1993; Zhu et al. 1993), expression
efﬁciency was assessed by measurement of b-galactosidase activity on
of wild-type pRB resulted in many enlarged ﬂat cells one of the four plates 2 d after transfection. Cells on the other plates
(ﬁg. 7A) and no colonies. In contrast, expression of were treated with puromycin for 18 d, and ﬂat cells were counted,
normalized for b-galactosidase activity, and plotted as shown; barspRBD24–25 did not induce ﬂat cells (ﬁg. 7A), similar to
indicate SD. Similar results were obtained in another experiment (datathe results seen with the null allele, pRBD21 (ﬁg. 7A)
not shown). B, Targeting pRBD24–25 to the nucleus, by use of a viral(Horowitz et al. 1989, 1990), and a similar number of
NLS. Saos-2 cells were transfected with plasmid vectors expressing
colonies grew on plates transfected with either D21 or the indicated proteins. Cellular localization of pRB was determined
D24–25 (data not shown). by immunostaining.
Restoration of Nuclear Localization of pRBD24–25:
growth suppression was not rescued or even improvedNo Recovery of Saos-2 Growth Suppression
(ﬁg. 7A). The low activity of pRBD24–25NLS was not dueSince pRBD24–25 partially represses E2F activity (ﬁg.
to an aberrant effect of the viral NLS, since wild-type5), a reduction in the number of ﬂat Saos-2 cells was
pRB modiﬁed in the same way suppressed growth, albeitexpected. Instead, the effect of D24–25 was as dramatic
at a slightly lower level (2.5-fold) than wild-type pRBas that of a null mutation. Thus, functions other than
(ﬁg. 7B; SVhRBNLS). These data further support the ideaE2F repression must be required for blocking of Saos-2
that E2F regulation alone is insufﬁcient to suppress Saos-cell growth. One possibility is that the combined effects
2 cell growth and demonstrate that nuclear targeting ofof D24–25 on both E2F regulation and nuclear localiza-
pRBD24–25 does not restore its ability to suppress Saos-tion severely impair growth suppression. Alternatively,
2 cells. Other functions that are affected by D24–25,the loss of other C-domain functions may be more crit-
such as interaction with MDM-2, must explain whyical.
pRBD24–25 cannot suppress the growth of these cells.To address the role of nuclear targeting in growth
However, the clinical LP phenotype suggests that thesuppression by pRBD24–25, the coding region for large T-
D24–25 allele can weakly suppress development of reti-antigen NLS was fused in-frame to the end of the coding
noblastoma tumors.sequence in SVhRBD24–25HA. The new plasmid,
SVhRBD24–25NLS, expressed a protein, pRBD24–25NLS, Discussion
that was targeted exclusively to the nucleus (ﬁg. 7B).
Clinical Impact of Identiﬁcation of LP MutationsRepression of E2F activity was slightly improved (1.7-
fold) by this modiﬁcation (data not shown). However, Mutation identiﬁcation permits accurate genetic
counseling, without which the developing retinoblas-despite this enhancement and the nuclear location,
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toma tumors might be missed in children of LP families mutagenesis studies. ManyRB mutations in other tumor
types are also null alleles (Harbour et al. 1988; Yokotawho are screened clinically on the basis of conventional
risk estimates. In the family reported here, the closest et al. 1988; Wadayama et al. 1994). A few mutations
have been observed that cause single-amino-acidaffected relative of IV-1, IV-2, IV-3, and IV-4, on the
basis of clinical diagnosis alone, was their grand-uncle, changes or in-frame deletions, both in retinoblastoma
(Kato and Wakabayashi 1988; Canning and DryjaII-2, so distantly related that conventional screening rec-
ommendations would not have required repeated clini- 1989; Yandell et al. 1989; Hashimoto et al. 1991;
Onadim et al. 1992; Blanquet et al. 1993; Dryja et al.cal examination. Fortunately, II-1 did not transmit the
D24–25 allele. Thus, identiﬁcation of the RB mutation 1993; Hogg et al. 1993; Cowell et al. 1994; Kato et al.
1994; Lohmann et al. 1994) and in other tumor typesis particularly signiﬁcant for LP families, where the pre-
ponderance of unaffected carriers might result in an un- (Horowitz et al. 1989, 1990; Bookstein et al. 1990; Kaye
et al. 1990; Shew et al. 1990; Scheffner et al. 1991). Inderestimate of risk.
In-frame mutations may be polymorphisms and might many of these cases, expression of the defective protein
has been documented in tumor and/or constitutionalrequire either clinical conﬁrmation that the DNA change
is causative (not present in the normal cells of either cells (Horowitz et al. 1989, 1990; Bookstein et al. 1990;
Kaye et al. 1990; Shew et al. 1990; Hashimoto et al.unilateral cases or the parent of bilateral cases) or func-
tion studies showing that the altered allele has deﬁcient 1991; Scheffner et al. 1991; Kato et al. 1994; Kratzke
et al. 1994). Signiﬁcantly, virtually all these mutationsactivity. In the large family RBF65, linkage of the D24–
25 allele to disease is very clear, since no one without disrupt the pocket domain. D24–25 is the ﬁrst example
of an in-frame deletion both affecting the pRB C-domainD24–25 had retinal alterations or transmitted the pre-
disposition to retinoblastoma. However, many individu- and shown to be expressed at the protein level, proving
that this region of pRB is functionally important in theals with D24–25 were asymptomatic, so, in the absence
of further function studies, the formal possibility would retina. A large deletion encompassing exons 24 and 25
has also been observed in a case of leukemia (Hansenexist that this mutation could be a polymorphism linked
to the real mutation, despite the important functions et al. 1990). However, it was not clear whether exon
23 was also affected, nor was expression of the mutantattributed to this region of pRB. Our function studies
strongly support the conclusion that D24–25 is the dis- allele veriﬁed.
ease-causing allele in RBF65. Similarly, the exon 4 dele-
Domain-Speciﬁc Patterns of LP Mutationstion that removes 40 amino acids from the N-domain
of pRB and is associated with LP retinoblastoma (Dryja Two large deletions have been identiﬁed that show
the LP phenotype: D24–25, which removes 58 residues,et al. 1993) could be a polymorphism, but separate stud-
ies suggest that large deletions in this region alter pRB and deletion of exon 4 (D4), which removes 40 amino
acids (Dryja et al. 1993). Both these sizable defects affectfunction (Hamel et al. 1990; Qian et al. 1992).
Germ-line RB mutations increase the risk of devel- regions outside the pocket domain. In contrast, identi-
ﬁed pocket LP mutations only affect one amino acidoping osteosarcoma as well as retinoblastoma. Given
that pRBD24–25 fails to suppress the growth of the Saos- (Onadim et al. 1992; Lohmann et al. 1994), suggesting
that in the critical pocket the types of mutations that2 osteosarcoma cell line, D24–25 may behave like a
high-penetrance mutation in bone. No RBF65 family can cause LP retinoblastoma are limited. Both small de-
letions and many substitutions of one or a few aminomembers have developed osteosarcoma, but this does
not negate the hypothesis, since, in one study, only 1/ acids in the pocket disrupt binding to E1A and to the
large T antigen (Hu et al. 1990; Kratzke et al. 1992;45 (2.2%) of patients with hereditary retinoblastoma
who did not receive radiation developed osteosarcoma Stirdivant et al. 1992), consistent with the idea that this
domain is very sensitive to perturbation.by 18 years of age (Draper et al. 1986), and since there
are only 18 D24–25 carriers in RBF65. However, until
Why D24–25 Is a Low-Penetrance Mutationadditional tumor data are obtained, the possibility that
some LP mutations behave as null alleles in nonretinal We identiﬁed several defects associated with D24–
25, each or all of which may explain why it causes LPtissues remains highly speculative.
retinoblastoma.
Functional Importance of the pRB C-Domain 1. Nuclear localization.—Previously, we had identi-
ﬁed a bipartite NLS within exon 25 of RB (human co-The identiﬁcation and characterization of weak RB
mutations is likely to generate new insight into the func- dons 860–876, mouse codons 853–869) (Zacksenhaus
et al. 1993). However, nuclear localization of pRB re-tion of this important growth-regulatory gene. The com-
mon types of clinical mutation causing retinoblastoma quires both the NLS and the pocket domain; mutation of
either region only partially disrupts nuclear localizationlead to premature termination of translation and to un-
detectable protein (Horowitz et al. 1990), so function (Zacksenhaus et al. 1993; Aguzzi et al. 1995). Expres-
sion of D24–25 in Saos-2 cells clearly showed cyto-information has come almost exclusively from in vitro
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plasmic and nuclear staining, consistent with an intact tion of these interactions does not cause high-penetrance
retinoblastoma.pocket domain allowing partial translocation into the
nucleus with E2F, as we have shown elsewhere for pRB First, MDM2-binding may be a nonessential function.
‘‘Nonessential’’ could mean either that this activity is(Zacksenhaus et al. 1996). Functionally, reduced nu-
clear localization may be similar to reduced expression redundant or that it is irrelevant. In this case, other
defects must explain the LP phenotype associated withof RB, which is the consequence of LP mutations in the
RB promoter (Sakai et al. 1991). D24–25. However, since MDM2 is clearly important in
the regulation of cell division and tumorigenesis (Fak-2. E2F repression.—Binding of pRB to E2F inhibits
the transcriptional activation domain (Flemington et al. harzadeh et al. 1991; Oliner et al. 1992, 1993; Finlay
1993; Ladanyi et al. 1993; Leach et al. 1993; Reifen-1993; Hagemeier et al. 1993b) and maintains in a re-
pressed state various genes required for S-phase (La berger et al. 1993; Cordon-Cardo et al. 1994; Lundgren
et al. 1997), it seems unlikely that its deregulation inThangue 1994; DeGregori et al. 1995; Duronio and
O’Farrell 1995; Ohtani and Nevins 1995). Although the the retina would have no effect.
Second, the simplest type of weak allele is one inpocket domain is sufﬁcient to bind free E2F, C-terminal
amino acids 793–869 are required for binding E2F on which an essential function is partially impaired, but it
is also possible that an LP mutation could completelyDNA (Hiebert 1993). Deletion of amino acids 841–850
or 841–909 disrupts binding of pRB to DNA-bound inactivate a semiessential function. Loss of a semiessen-
tial activity might contribute to tumorigenesis only ifE2F and reduces—but does not abrogate—repression
of the adenovirus E2 promoter by pRB (Hiebert 1993). other pRB functions were also diminished—that is,
when the normal RB allele sustained a null mutation.D24–25 removes amino acids 830–887, so the residual
repression of E2F-mediated transcription by pRBD24–25 Third, some LP mutations may create ‘‘death alleles’’
rather than weak alleles: in this model, duplication ofis probably mediated by binding to free E2F, either (a)
in the cytoplasm, in the absence of the NLS, or (b) more the LP mutation by LOH would result in cell death,
potentially because of the conﬂicting signals generatedefﬁciently, in the nucleus, when an NLS is provided
(pRBD24–25NLS). We have shown that repression of tran- by a partially functional pRB molecule. The retina
would still be protected from cancer in this scenario.scription from a simple promoter requires only binding
of pRB to E2F (which would be intact for pRBD24–25) Presumably, a null mutation of the normal allele would
alter the balance toward tumorigenesis rather than to-but that silencing of a complex promoter requires pRB
to bind to E2F on DNA (which would be deﬁcient for ward apoptosis. Mice may also be protected from retino-
blastoma because loss of the RB gene leads to apoptosispRBD24–25), where it presumably interacts with other
transcription factors (Zacksenhaus et al. 1996). The par- (Maandag et al. 1994), so it is possible that, under cer-
tain conditions, this is also the outcome in the humantial effect of D24–25 on E2F repression is consistent
with the idea of a weak allele that, when duplicated by retina.
Finally, in a ‘‘three-hit’’ model, abrogation of a pRBLOH, still blocks tumorigenesis.
3. MDM2 binding.—MDM2 is a widely expressed function, such as MDM2-binding, would not lead to
tumorigenesis but would only prime the cell so that aprotein (de Oca Luna et al. 1996) that binds to the C-
domain of pRB, between amino acids 792 and 928 (Xiao third mutation, perhaps at an oncogene, would initiate
retinoblastoma. Tumor frequency would be low becauseet al. 1995). D24–25, which deletes residues 830–887,
ablated interaction of pRB with MDM2, even in a low- of the requirement for an additional event. All retino-
blastomas have, besides RB defects, additional geneticstringency binding assay.
Abrogation of any function by an LP mutation raises changes, such as the iso(6p) chromosomal rearrange-
ment (Squire et al. 1984) or the K-ras mutation (Bautistaan interesting dilemma. According to the weak-allele
hypothesis, a homozygous LP mutation is nontumori- et al. 1996), supporting the idea that other mutations
facilitate retinoblastoma.genic, and tumors form only if the second hit is a distinct
null mutation. Duplication of D24–25 would generate Although RB//- mice are resistant to retinoblastoma,
100% develop pituitary middle-lobe tumors at 2–11 moa retinal cell in which pRB cannot bind and regulate
either MDM2 or other proteins that bind to the same of age, and the tumors always show LOH for the RB
null allele (Jacks et al. 1992; Hu et al. 1994; Harrisondomain, such as c-ABL (Welch andWang 1993). If these
interactions were essential for tumor suppression in the et al. 1995). The tumor frequency suggests that, as in
human retinoblastoma, two hits are rate-limiting for tu-retina, D24–25 would be a high-penetrance mutation.
One explanation is that these interactions exist only to mor development (Hu et al. 1994). Thus, at the genetic
level, human retinoblastoma and mouse pituitary mid-inhibit pRB, in which case their loss would potentiate,
rather than impair, pRB function. However, if it is as- dle-lobe tumors bear a striking resemblance. Some in-
sight into LP retinoblastoma may come, therefore, fromsumed that pRB also negatively regulates MdM2 and/
or additional C-domain–binding proteins, other analysis of the effect of LP RB mutations on mouse
pituitary tumorigenesis. For example, a homozygoushypotheses, outlined below, may explain why abroga-
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weak allele or death allele should not generate tumors, agreement, Sellers et al. (1995) have recently shown that
a heterologous repression domain fused to E2F-1 shutsbut in the three-hit model a small proportion of tumors
are predicted to be homozygous for the LP allele. Gener- down expression of E2F-regulated genes but does not
suppress the growth of Saos-2 cells. Additional effectsation of mice homozygous for an LP mutation may help
distinguish between weak alleles and death alleles, on of pRB are therefore implicated. We have shown that
targeting pRBD24–25 to the nucleus did not improvethe basis of the level of apoptosis in different tissues.
Several groups have shown that pRB is cleaved by a growth suppression. However, interaction of pRB with
MDM2 was completely ablated by D24–25, suggestingmember of the caspase (interleukin-1b-converting en-
zyme–related) family of proteases during apoptosis (An that perhaps this or a related interaction is essential for
growth suppression in Saos-2 cells. c-ABL, like MDM2,et al. 1996; Janicke et al. 1996; Chen et al. 1997; Tan
et al. 1997). Digestion occurs at a caspase consensus binds the pRB C-domain (Welch and Wang 1993), and
it is likely that this interaction is also ablated by D24–cleavage-recognition site (DEADG) between positions
883 and 887 in the pRB C-terminal domain (Janicke et 25. Wang’s group has shown that suppression of Saos-
2 cell growth requires the assembly of multiple proteinsal. 1996; Chen et al. 1997; Tan et al. 1997). Mutation
of this site blocks caspase-mediated cleavage of pRB and in one complex by different pRB-binding domains
(Welch and Wang 1995a, 1995b). This ‘‘matchmaker’’enhances resistance to tumor necrosis factor a–induced
apoptosis (Janicke et al. 1996; Tan et al. 1997). This function may not be as critical in the retina, where D24–
25 behaves as an LP allele, as it is in Saos-2 cells.site is deleted in pRBD24–25, and could render retinal cells
more resistant to apoptotic stimuli. Duplication of such
Retinoblastoma and Homozygous LP Allelesan allele may cause retinoblastoma only if, subsequently,
The weak-allele hypothesis predicts that a homozy-another locus is mutated (the three hit hypothesis).
gous LP allele is nontumorigenic (Sakai et al. 1991).Again, insight into this issue may be gained from de-
Few tumors are available from LP families to deter-termining the in vivo effect of mutation of the mouse
mine whether this assumption is correct. In one exam-pRB DEADG sequence.
ple, a tumor was shown to be heterozygous, and the
Multiple pRB Growth-Suppression Domains? second allele had sustained a distinct null mutation
(Dryja et al. 1993). In another family, LOH was ob-D24–25 behaved like a null allele in the Saos-2
served in the retinoblastoma, but quantitation was notgrowth assay, consistent with the idea that growth sup-
possible, so it was uncertain whether LOH was due topression in the retina, where D24–25 has some antitu-
hemi- or homozygosity (Lohmann et al. 1994). Nomorigenic activity, may involve protein domains differ-
retinoblastoma tumor was or is likely to be availableent than those involved in other tissues. Two other
from the RBF65 family, since tiny tumors are curedobservations are consistent with this idea. First, the LP
without surgery. The melanoma from III-9 did notmutation, Arg661Trp, which has the same retinal phe-
show LOH and may have arisen from a separate null-notype as does D24–25, behaves like wild-type pRB in
RB second hit, or it could be unlinked to the RB muta-suppressing the growth of a lung-carcinoma cell line
tion. Melanoma is a common second tumor in individ-(Kratzke et al. 1994). Thus, in three different cell types,
uals with RB mutations (Eng et al. 1993). The issueosteosarcoma, lung carcinoma, and retinal cells, LP mu-
of whether homozygous LP mutations are ever tumori-tations have quite different effects. Second, although a
genic remains unsolved. In the three-hit hypothesis forstop codon in RB exon 3 renders mice susceptible to
LP retinoblastoma, discussed above, LOH would beboth thyroid and pituitary tumors, a similar defect in
observed in some tumors.either exon 19 or exon 20 is associated only with pitu-
itary tumors (Hu et al. 1994; Maandag et al. 1994;
Williams et al. 1994; Harrison et al. 1995). Small
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